753 related articles for article (PubMed ID: 31476800)
1. Hypofractionation for clinically localized prostate cancer.
Hickey BE; James ML; Daly T; Soh FY; Jeffery M
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011462. PubMed ID: 31476800
[TBL] [Abstract][Full Text] [Related]
2. Dose-escalated radiotherapy for clinically localized and locally advanced prostate cancer.
Kim S; Kong JH; Lee Y; Lee JY; Kang TW; Kong TH; Kim MH; You SH
Cochrane Database Syst Rev; 2023 Mar; 3(3):CD012817. PubMed ID: 36884035
[TBL] [Abstract][Full Text] [Related]
3. External beam radiation dose escalation for high grade glioma.
Khan L; Soliman H; Sahgal A; Perry J; Xu W; Tsao MN
Cochrane Database Syst Rev; 2020 May; 5(5):CD011475. PubMed ID: 32437039
[TBL] [Abstract][Full Text] [Related]
4. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
5. Posterior musculofascial reconstruction in robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer.
Rosenberg JE; Jung JH; Lee H; Lee S; Bakker CJ; Dahm P
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD013677. PubMed ID: 34365635
[TBL] [Abstract][Full Text] [Related]
6. Retzius-sparing versus standard robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer.
Rosenberg JE; Jung JH; Edgerton Z; Lee H; Lee S; Bakker CJ; Dahm P
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD013641. PubMed ID: 32813279
[TBL] [Abstract][Full Text] [Related]
7. Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer: A Meta-analysis of Randomized Noninferiority Trials.
Royce TJ; Lee DH; Keum N; Permpalung N; Chiew CJ; Epstein S; Pluchino KM; D'Amico AV
Eur Urol Focus; 2019 Jul; 5(4):577-584. PubMed ID: 29221876
[TBL] [Abstract][Full Text] [Related]
8. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Jakob T; Tesfamariam YM; Macherey S; Kuhr K; Adams A; Monsef I; Heidenreich A; Skoetz N
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013020. PubMed ID: 33270906
[TBL] [Abstract][Full Text] [Related]
12. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
[TBL] [Abstract][Full Text] [Related]
13. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
14. Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers.
Lawrie TA; Green JT; Beresford M; Wedlake L; Burden S; Davidson SE; Lal S; Henson CC; Andreyev HJN
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD012529. PubMed ID: 29360138
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy for metastatic renal cell carcinoma.
Hofmann F; Hwang EC; Lam TB; Bex A; Yuan Y; Marconi LS; Ljungberg B
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012796. PubMed ID: 33058158
[TBL] [Abstract][Full Text] [Related]
16. Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer.
Kunath F; Jensen K; Pinart M; Kahlmeyer A; Schmidt S; Price CL; Lieb V; Dahm P
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD003506. PubMed ID: 31194882
[TBL] [Abstract][Full Text] [Related]
17. Degarelix for treating advanced hormone-sensitive prostate cancer.
Zengerling F; Jakob JJ; Schmidt S; Meerpohl JJ; Blümle A; Schmucker C; Mayer B; Kunath F
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD012548. PubMed ID: 34350976
[TBL] [Abstract][Full Text] [Related]
18. Partial breast irradiation versus whole breast radiotherapy for early breast cancer.
Hickey BE; Lehman M
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD007077. PubMed ID: 34459500
[TBL] [Abstract][Full Text] [Related]
19. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
[TBL] [Abstract][Full Text] [Related]
20. External beam radiation dose escalation for high grade glioma.
Khan L; Soliman H; Sahgal A; Perry J; Xu W; Tsao MN
Cochrane Database Syst Rev; 2016 Aug; (8):CD011475. PubMed ID: 27541334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]